Desmopressin

also known as: DDAVP, 1-deamino-8-D-arginine vasopressin, dDAVP, Stimate, Minirin, Noctiva, Nocdurna

DDAVP — the classic V2-selective vasopressin analog. FDA-approved February 1978 for central diabetes insipidus; decades of label expansion added primary nocturnal enuresis, nocturia (Noctiva / Nocdurna), and hemostatic use in mild hemophilia A and type 1 von Willebrand disease. WHO Essential Medicines List.

A synthetic nonapeptide with two modifications from native arginine vasopressin: removal of the N-terminal amine (1-deamino) and substitution of D-arginine for L-arginine at position 8. These changes produce >4,000-fold selectivity for the renal V2 receptor (antidiuretic) over the vascular V1a receptor (pressor), give a clinically useful 6–14 hour duration of action (versus 10–35 minutes for vasopressin), and retain the hemostatic activity mediated through release of factor VIII and von Willebrand factor from vascular endothelial Weibel-Palade bodies. Originally developed by Ferring Pharmaceuticals; first clinical use 1974; FDA-approved February 1978 for central diabetes insipidus; subsequently approved for primary nocturnal enuresis in children ≥6, for nocturia (Noctiva intranasal 2017; Nocdurna sublingual 2018), and established by label and off-label use for hemophilia A / von Willebrand type 1. Multiple routes of administration: intranasal, oral tablet, sublingual melt, and intravenous.

Mechanism of action

V2-selective agonist. V2 receptor activation on renal collecting-duct principal cells couples to Gs / adenylate cyclase / cAMP, activating protein kinase A, which phosphorylates aquaporin-2 and drives its insertion into the apical plasma membrane — increasing water permeability and free-water reabsorption. The hemostatic effect arises from V2 receptor activation on vascular endothelial cells (Weibel-Palade bodies), triggering release of preformed von Willebrand factor and (indirectly) factor VIII into plasma — a 2-to-4-fold rise that can correct bleeding in mild hemophilia A and type 1 vWD without transfusion of blood products. The absence of V1a activity means no vasoconstriction and no pressor effect at therapeutic doses.

Primary uses

Central diabetes insipidus (FDA-approved)
Primary nocturnal enuresis (FDA-approved oral; pediatric intranasal label discontinued 2007)
Nocturia due to nocturnal polyuria (FDA-approved sublingual Nocdurna)
Mild hemophilia A (factor VIII activity >5%)
Type 1 von Willebrand disease
Uremic bleeding (off-label)

Typical dosing

0.05–1.2 mg (oral tablet), 10–40 mcg (intranasal), 0.3 mcg/kg (IV for hemostasis) once to twice daily for chronic indications; single dose for hemostasis (oral, intranasal, sublingual, intravenous, subcutaneous)

Dose individualised by indication and response. Severe hyponatremia is the principal safety concern — fluid restriction is essential, particularly in children and elderly. Hemostatic use: maximum benefit at first dose; tachyphylaxis typically after 2–3 consecutive doses.

Regulatory status

FDA-approved February 1978 for central diabetes insipidus (DDAVP®, Ferring). Subsequent approvals: primary nocturnal enuresis in children ≥6 (oral tablet 1995; intranasal spray withdrawn for pediatric PNE in 2007 after hyponatremia/seizure safety signal); mild hemophilia A and type 1 von Willebrand disease (Stimate® intranasal); nocturia due to nocturnal polyuria (Noctiva® intranasal March 2017, Avadel — later discontinued; Nocdurna® sublingual June 2018, Ferring). WHO Essential Medicines List. Generic formulations widely available.

References

[fda-pi] DDAVP® (desmopressin acetate) Prescribing Information. Ferring Pharmaceuticals. Initial US approval February 1978.
[fda-pi] Nocdurna® (desmopressin acetate) sublingual tablets Prescribing Information. Ferring Pharmaceuticals. Approved June 2018.
[review] Mannucci PM. "Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years." Blood, 1997;90(7):2515-2521.

Related peptides

Vasopressin

Vasostrict — the endogenous antidiuretic hormone as an ICU vasopressor. FDA-approved April 2014 for adults with vasodilatory shock (post-cardiotomy, sepsis) who remain hypotensive despite fluids and catecholamines. Works through V1a receptors on vascular smooth muscle — a receptor axis pharmacologically distinct from catecholamine receptors, preserving its vasopressor effect when adrenergic receptors are desensitised.

Terlipressin

Terlivaz — the first and only FDA-approved drug for hepatorenal syndrome (HRS). FDA-approved September 2022 (Mallinckrodt) for adults with HRS with rapid reduction in kidney function, after a multi-decade regulatory history including four prior Complete Response Letters and the successful CONFIRM Phase 3 trial (NEJM 2021).

Quick facts

Class

A synthetic V2-selective vasopressin analog (1-deamino-8-D-arginine vasopressin) developed by Ferring in the late 1960s, engineered for long duration, minimal V1 vasopressor activity, and broad clinical utility across central diabetes insipidus, primary nocturnal enuresis, nocturia, hemophilia A, and von Willebrand disease type 1.

Subcategory

V2-selective vasopressin receptor agonist

Sequence

Mpa-Tyr-Phe-Gln-Asn-Cys-Pro-D-Arg-Gly-NH2 (disulfide Mpa1-Cys6; Mpa = 3-mercaptopropionic acid)

Molecular formula

C46H64N14O12S2

Molecular weight

1069.22 Da

Half-life

1.5–3 hours (plasma); clinical antidiuretic effect 6–14 hours — Plasma half-life is short but clinical effect is prolonged by tight V2 receptor engagement and slow dissociation. Hemostatic effect peaks 30–90 minutes post-dose.

Evidence level

High

Disclaimer

This entry is for educational purposes only and does not constitute medical advice. Dosing information reflects published regulatory or research data and is not a recommendation. Many compounds described here are not approved for human use in the United States. Consult a licensed medical professional before considering any peptide therapy.